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Background: Despite genetic polymorphism in response to platinum/5-Fu chemotherapy in gastric cancer (GC) has
been studied, data reported so far are conflicting and critical consideration is needed before translation to the
treatment of GC.
Methods: We performed a meta-analysis by using 20 eligible studies to examine polymorphisms of ERCC1, GSTs, TS
and MTHFR in predicting clinical outcomes (response rate, overall survival and toxicity) of GC patients treated with
platinum/5-Fu-based chemotherapy. The association was measured using random/fixed effect odds ratios (ORs) or
hazard ratios (HRs) combined with their 95% confidence intervals (CIs) according to the studies’ heterogeneity.
Statistical analysis was performed with the software STATA 9.0 package.
Results: No significant association was found between response rate and genetic polymorphism in TS, MTHFR,
ERCC1, GSTM1 and GSTP1. However, response rate was higher in GSTT1 (+) genotype compared with GSTT1 (−)
genotype (T-/T+: OR=0.67, 95% CI: 0.47–0.97). With regard to long term outcomes, we could observe a significant
longer overall survival in TS 3R/3R [(2R2R+2R3R)/3R3R: HR=1.29, 95% CI: 1.02–1.64] and GSTP1 GG/GA [(GG+AG)/AA:
HR=0.51, 95% CI: (0.39, 0.67)] genotypes. In addition, significant association was demonstrated between toxicity and
genetic polymorphism in TS, MTHFR and GSTP1 in included studies.
Conclusion: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC
patients treated with platinum/5-Fu-based chemotherapy. Studies with large sample size using the method of
multi-variant analyses may help us to give more persuasive data on the putative association in future.
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In worldwide, gastric cancer (GC) remains one of the
major causes of cancer-related death worldwide [1]. Sur-
gery is the primary modality for managing early-stage
and locally-advanced disease. However, even after gas-
trectomy, many patients relapse with local recurrence or
distant metastasis [2]. In addition, approximately 20–
30% of patients have inoperable disease at diagnosis.
Therefore, the majority of patients need a systemic ther-
apy at some point in their disease.* Correspondence: gxhans@163.com; qxgnn001@163.com
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reproduction in any medium, provided the orPalliative chemotherapy for advanced GC has been
widely accepted as a standard treatment for several dec-
ades. And recent studies have demonstrated that peri-
operative adjuvant chemotherapy (pre- or post-operative)
can improve survival and quality of life in patients with
GC [3]; however, expected survival for the advanced dis-
ease is generally poor (less than 1 year). Until now, 5-
fluorouracil (5-Fu) and platinum are the most common
drugs used for GC both in adjuvant and advanced settings,
although there are no standard combination regimens [4].
Additionally, efficacy outcomes for a number of new
agents (such as paclitaxel, oxaliplatin and capecitabine)
have not shown definitive clinical benefit or superiority tois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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some patients therapy results in severe, unpredictable tox-
icity without any tumor response. Consequently, in order
to allow the discernment of patients in whom a particular
therapy will exert a real benefit, it is crucial to identify fac-
tors relevant to response to fluorouracil/platinum as well
as factors predisposed to the development of severe tox-
icity. In this regard, pharmacogenetics, a research field
identifying inherited genetic variability which may affect
treatment outcomes, could allow a tailored management
regimen that maximizes clinical response while limiting
the adverse effects of treatment [8,9].
A growing body of evidence suggests that inter-
individual variation in drug-metabolizing enzymes and
nucleotide excision repair (NER) system may affect
anticancer drug efficacy by influencing DNA repair or
related enzyme activities [10]. Recently, many studies
finds that genes involved in DNA detoxification (gluta-
thione S-transferases, GSTs) and repair (excision repair
cross complementing 1, ERCC1) control the effects of
platinum [11,12], while methylene tetrahydrofolate re-
ductase (MTHFR) and thymidylate synthase (TS) are
associated with 5-Fu metabolism [11,13]. Despite genetic
polymorphism in response to platinum/5-Fu chemother-
apy in GC has been reported [14], data reported so far
are conflicting and critical consideration is needed before
translation to the treatment of GC. Therefore, a systematic
review is solely needed to provide a comprehensive and up-
to-date overview concerning possible roles for genetic poly-
morphisms in GC treatment.
In this study, we assessed literatures existing and con-
ducted a meta-analysis to examine polymorphisms of
ERCC1, GSTs, TS and MTHFR in predicting clinical out-




A computer-aided search of the Pubmed/Medline and
Embase was performed to identify relevant and available
published articles by using the following search phrases:
gastric cancer/carcinoma/tumor/tumour/neoplasm, stomach
cancer/carcinoma/tumor/tumour/neoplasm, polymorphism/
polymorphisms and chemotherapy. The upper limit of
search date was not limited, and the lower limit was
January 2012. Both free text and MeSH search for key-
words were employed. The language that the papers were
written in was not restricted. To identify more potentially
relevant studies, reference lists from selected studies
through electronic searching were hand searched.
Inclusion and exclusion criteria
The inclusion criteria of this meta-analysis were as fol-
lows: 1) pathologically confirmed GC with a measurablelesion; 2) no concurrent uncontrolled medical illness; 3)
patients receiving no other adjuvant treatment, such as
radiotherapy or immunotherapy; 4) clinical outcomes
[response rate (RR), overall survival (OS) or toxicity)
about genetic polymorphisms [ERCC1-118, GSTs (GSTM1,
GSTP1-105 or GSTT1), TS 5’-untranslated region or
MTHFR-667] in GC patients treated with platinum/
5-Fu-based chemotherapy were reported.
The exclusion criteria were: 1) included patients with
carcinoma other than the stomach; 2) in vitro studies; 3)
studies were not original research, such as review article;
4) platinum/5-Fu were not included in the chemothera-
peutic regimens. We included literatures with largest
sample size for repetitive publications.
Data extraction
Two authors (Zhen Wang and Jun-qiang Chen)
extracted data independently from all eligible studies
using predefined tables, which included items as follows:
first author, publication time, country and ethnicity of
the patients, molecular marker, sample size, evaluation
criteria, chemotherapeutic regimens and clinical out-
comes (RR, OS and toxicity). If necessary, the authors of
the original literatures were contacted for available data.
Disagreements were resolved by consensus.
Statistical analysis
Hazard ratios (HRs) and their 95% confidence intervals
(CIs) for OS were obtained from each primary study. In
case the data were not directly recorded in primary
reports, we calculated HR and their 95% CIs from the
survival curves using published methodology [15,16].
Kaplan–Meier curves of included studies were read by
Engauge Digitizer version 2.11 (free software downloaded
from http://sourceforge.net). HR calculation spreadsheet
was freely downloaded from http://www.trialsjournal.
com/content/supplementary/1745-6215-8-16-s1.xls. The
odds ratio (OR) for RR and HRs for OS were calculated
based on a fixed-effect model first by using STATA 9.0
package. Heterogeneity between included studies was
tested using χ2 test (considered significant if P<0.10). If
heterogeneities were present, one of the following mea-
sures was used to attempt to explain them: (1) subgroup
analysis; (2) sensitivity analysis; or (3) random-effect
model for meta-analysis. All P values were two-sided and
all CIs had a two-sided probability coverage of 95%.
Results
Study selection and description
According to the search strategy referred, a total of 224
literatures were yielded: 130 in PubMed and 94 in
EMBASE. By browsing the titles and abstracts, we found
that lots of articles were irrelevant and some were iden-
tified duplicately, thus 69 articles remained for potential
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reviewing the full text, 49 literatures were excluded. The
main reasons for excluding studies were as follows: study
type (review articles and in vitro studies), participants
(inclusion of patients with carcinoma other than the
stomach), interventions (exclusion of platinum/5-Fu in
the chemotherapeutic regimens) and repetitive publica-
tion. Finally 20 studies (2189 patients) were considered
eligible for inclusion [11,14,17-34]. The process of study
selection was listed in Figure 1.
Among the 20 included studies, the number of TS,
MTHFR, ERCC1 and GSTs polymorphism study was 10
(952 patients), 9 (988 patients), 10 (1080 patients) and
10 (1187 patients), respectively. The sample size varied
from 25 to 200 and the publication time was from 2002
to 2011. Participants were Asian and European. The
main characteristics of the 20 included studies were
listed in Table 1.
Association between TS, MTHFR polymorphism and 5-Fu
based chemotherapy
Response rate (RR)
Five studies (534 patients) reported the association
between TS polymorphism and RR [11,14,19,31,32].Potentially relevant studies identified
through database searching n=224
Potentially relevant titles and abstracts 
were screened n =152
Potentially relevant fultexts were 
retrieved n=69
Studies included in meta-analysis
n=20
Figure 1 QUORUM flow chart for studies.P value of heterogeneity test was 0.471 and a fixed-effect
model was used. The pooled analysis showed that there
was no significant difference between RR of patients
with the 3R/3R genotype and that of patients with the
2R/3R and 2R/2R genotypes [(2R2R+2R3R)/3R3R:
OR=0.92, 95% CI: 0.62–1.37]. Considering that RR might
be influenced by ethnicity, evaluation criteria and the
purpose of chemotherapy, we performed subgroup ana-
lysis. And no association was observed between TS poly-
morphism and RR by using the method of subgroup
analysis (Table 2).
Data of 5 included studies (571 patients) were applicable
for analyzing the association between MTHFR poly-
morphism and RR [11,14,25,31,32]. P value of heterogen-
eity test was less than 0.1 and a random-effect model was
used. Combined analysis demonstrated that there was no
significant difference between RR of patients with C/C
genotype and that of patients with the C/T and T/T geno-
type [(CT+TT)/CC: OR=1.12, 95% CI: 0.49–2.55]. In
order to explore sources of heterogeneity, we performed
subgroup analysis. The results of subgroup analysis
showed that no significant association except Asian and
WHO subgroups, where only one included studies
reported [25] a significantly higher RR in C/T or T/TDuplicates removed n=72
Irrelevant titles or abstracts n=83
Review articles n=18
In vitro studies n=6
Patients with carcinoma other than the 
stomach were included n=13
Platinum/5-Fu were not included in the 
chemotherapeutic regimens n=7
Repetitive publication n=5
Table 1 Characteristics of studies included in the systematic review











RECIST 52 5-Fu+cisplatin + leucovorin RR and OS
Ruzzo 2006 [14] Patients with advanced GC TS, GSTs, MTHFR,
ERCC1-118
European (Italy) Others 175 fluorouracil/cisplatin RR and OS
Shim 2010 [17] Patients with recurrent or metastatic GC GSTs Asian (Korea) RECIST 200 Paclitaxel/docetaxel +cisplatin RR and OS
Park 2011 [18] Patients with metastatic GC ERCC1-118 Asian (Korea) RECIST 108 S-1 + cisplatin RR and OS
Han 2010 [19] Patients with recurrent or metastatic GC TS, ERCC1-118 Asian (Korea) RECIST 38 5-Fu+leucovorin +oxaliplatin RR and OS
Stocker 2009 [20] Neoadjuvant chemotherapy for locally
advanced GC without distant metastasis
ERCC1-118 European
(Germany)
Others 178 5-Fu+leucovorin +cisplatin RR and OS
Seo 2009 [21] Patients with recurrent or metastatic GC TS, GSTs, ERCC1-118 Asian (Korea) RECIST 94 5-Fu+ oxaliplatin/irinotecan RR, OS and
toxicity
Liu 2011 [22] Patients with advanced GC GSTs, ERCC1-118 Asian (China) NR 126 5-FU+leucovorin +oxaliplatin OS
Ott 2008 [23] Neoadjuvant chemotherapy for locally
advanced GC without distant metastasis
GSTs European
(Germany)
Others 139 5-Fu+leucovorin + cisplatin RR and OS
Li 2010 [24] Patients with advanced GC GSTs Asian (China) Others 92 5-Fu +oxaliplatin RR, OS and
toxicity
Lu 2004 [25] Patients with advanced GC MTHFR Asian (China) WHO 75 5-Fu+leucovorin RR and toxicity
Huang 2009 [26] Patients with GC after curative surgery GSTs, ERCC1-118 Asian (China) NR 102 5-Fu+leucovorin +oxaliplatin OS
Shitara 2010 [27] Patients with inoperable GC TS, MTHFR Asian (Japan) NR 132 5-Fu et al. OS and toxicity
Huang 2009 [28] Patients with GC after curative surgery TS, MTHFR Asian (China) NR 116 5-Fu+leucovorin et al. OS
Ishida 2002 [29] Patients with GC after surgery TS Asian (Japan) NR 51 5-Fu et al. OS
Keam 2008 [30] Patients with recurrent or metastatic GC GSTs, ERCC1-118 Asian (Korea) WHO 73 5-Fu+leucovorin +oxaliplatin RR and OS








Ott 2006 [32] Neoadjuvant chemotherapy for
patients with locally advanced GC
TS, MTHFR European
(Germany)
Others 135 5-Fu+cisplatin RR and OS
Ott 2011 [33] Neoadjuvant chemotherapy for
patients with locally advanced GC
MTHFR European
(Germany)
Others 144 5-Fu+leucovorin + cisplatin OS
Lee 2005 [34] Patients with advanced GC TS, MTHFR Asian (Korea) NR 25 5-Fu et al. OS



















Table 2 The association between TS polymorphism and clinical outcomes
Study (reference) RR (n/N) OS (HR, 95% CI) Toxicity
Goekkurt 2006 [11] 3R3R: 3/12; 2R2R+2R3R: 9/32 NR NR
Ruzzo 2006 [14] 3R3R: 22/61; 2R2R+2R3R: 48/114 NR NR
Han 2010 [19] 3R3R: 16/28; 2R2R+2R3R: 5/10 NR NR
Seo 2009 [21] NR NR NSS
Shitara 2010 [27] NR (2R2R+2R3R)/3R3R: 1.28 (0.85, 1.96) NSS
Huang 2009 [28] NR (2R2R+2R3R)/3R3R: 1.54 (0.879, 2.698) NR
Ishida 2002 [29] NR (2R2R+2R3R)/3R3R: 1.26 (0.81, 1.95) NR
Goekkurt 2009 [31] 3R3R: 17/33; 2R2R+2R3R: 35/101 NR Grade 3/4 leukopenia: P=0.047
Ott 2006 [32] 3R3R: 10/41; 2R2R+2R3R: 23/94 2R2R/3R3R: 0.33 (0.22, 0.51); 2R3R/3R3R:
0.52 (0.37, 0.74)
NR
Lee 2005 [34] NR (2R2R+2R3R)/3R3R: 1.16 (0.68, 1.99) NR
Combined analysis(OR/HR, 95CI %) OR: (2R2R+2R3R)/3R3R (2R2R+2R3R)/3R3R ___
Total: 0.92 (0.62, 1.37); Total: 1.29 (1.02, 1.64)
RECIST subgroup: 0.93 (0.33, 2.63); All studies reported the data were Asian
Others subgroup: 0.92 (0.60, 1.41); Palliative subgroup: 1.16 (0.68, 1.98)
Asian subgroup: 0.75 (0.18, 3.19); Adjuvant subgroup: 1.33 (1.02, 1.73)
European subgroup: 0.94 (0.62, 1.41)
Palliative subgroup: 0.90 (0.58, 1.40)
Neoadjuvant subgroup: 1.00 (0.43, 2.36)
RR: response rate; OS: overall survival; OR: odds ratio; HR: hazard ratio; NR: not reporting; NSS: no statistical significance.
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CI: 1.5–33.53; Table 3).
Overall survival (OS)
Five studies (459 patients) reported the association be-
tween TS polymorphism and OS [27-29,32,34], but the
data reported by Ott et al. could not be used for com-
bined analysis [32], which showed that 2R/2R or 2R/3R
genotypes were significantly associated with a favorable
OS (2R2R/3R3R: HR=0.33, 95% CI: 0.22–0.51; 2R3R/
3R3R: HR=0.52, 95% CI: 0.37–0.74). Therefore, data
from 4 Asian studies (324 patients) were combined
[27-29,34]. P value of heterogeneity test was 0.909
and a fixed-effect model was used. Meta-analysis
showed that a significantly longer OS was observed
in 3R/3R genotype compared with the 2R/2R or 2R/
3R genotypes [(2R2R+2R3R)/3R3R: HR=1.29, 95% CI:
1.02–1.64; Table 2]. (Additional file 1: Figure S1).
When considering the purpose of chemotherapy, we
found significant association in adjuvant subgroup
but no significance in palliative subgroup (Table 2).
Data of 5 included studies (552 patients) were applic-
able for analyzing the association between MTHFR
polymorphism and OS [27,28,32-34], but the data
reported by Shitara et al. and Huang et al. could not be
used for combined analysis [27,28]. These two studies
reported patients with TT genotype had a longer OS
compared with the C/T or C/C genotypes; although thedifference was not statistically significant in the study
by Huang et al. (Table 3). Therefore, data of 3 included
studies (323 patients) were pooled [32-34]. Meta-
analysis showed no significant association was seen be-
tween MTHFR polymorphism and OS (CT/CC:
HR=1.10, 95% CI: 0.67–1.79; TT/CC: HR=0.94, 95% CI:
0.65–1.37). Additionally, subgroup analysis did not
demonstrate significant difference (Table 3). (Additional
file 2: Figure S2)Toxicity
Because different evaluation criteria were used and very
few studies reported the results, we did not combine the
data. Three studies (360 patients) reported the associ-
ation between TS polymorphism and toxicity [21,27,31].
Two studies found no significant genetic type was
observed in conjunction with TS polymorphism [21,27];
but Goekkurt et al. reported that carriers of at least one
3R haplotype were at lower risk for developing grade 3/4
leukopenia with an OR of 0.12 (95% CI: 0.02-0.88) [31].
Data of 3 included studies (341 patients) were applic-
able for analyzing the association between MTHFR poly-
morphism and toxicity [25,27,31]. Two studies found no
significant association between MTHFR polymorphism
and toxicity [27,31]; however, Lu et al. reported that
MTHFR TT was associated with higher frequency of
nonhematologic toxicity (nausea/vomiting) [25].
Table 3 The association between MTHFR polymorphism and clinical outcomes
Study (reference) RR (n/N) OS (HR, 95% CI) Toxicity
Goekkurt 2006 [11] CC: 10/28; CT+TT: 3/22 NR NR
Ruzzo 2006 [14] CC: 13/34; CT+TT: 57/141 NR NR
Lu 2004 [25] CC: 2/24; CT+TT: 20/51 NR Nausea/vomiting:
P=0.002
Shitara 2010 [27] NR TT/(CT+CC): 0.57 (0.33, 0.97) NSS
Huang 2009 [28] NR TT/(CT+CC): 0.595 (0.349, 1.012) NR
Goekkurt 2009 [31] CC: 18/59; CT+TT: 34/75 NR NSS
Ott 2006 [32] CC: 16/50; CT+TT: 17/85 CT/CC: 1.8 (1.13, 2.88); TT/CC: 0.93 (0.54, 1.62) NR
Ott 2011 [33] NR CT/CC: 0.8 (0.50, 1.36); TT/CC: 0.5 (0.18, 1.49) NR
Lee 2005 [34] NR CT/CC: 0.91 (0.58, 1.43); TT/CC: 1.16 (0.65, 2.08) NR
Combined analysis
(OR/HR, 95CI %)
OR: (CT+TT)/CC CT/CC (total): 1.10 (0.67, 1.79); ___
Total: 1.12 (0.49, 2.55); RECIST subgroup:
0.28 (0.07, 1.20);
CT/CC (Asian subgroup): 0.91 (0.58, 1.43);
WHO subgroup: 7.1 (1.5, 33.53); CT/CC (European subgroup): 1.21 (0.54, 2.67);
Others subgroup: 1.05 (0.51, 2.16); CT/CC (Palliative subgroup): 0.91 (0.58, 1.43);
Asian subgroup: 7.1 (1.5, 33.53); CT/CC (Neoadjuvant subgroup): 1.21 (0.54, 2.67) TT/CC
(total): 0.94 (0.65, 1.37);
European subgroup: 0.85 (0.41, 1.77) TT/CC (Asian subgroup): 1.16 (0.65, 2.08);
Palliative subgroup: 1.40 (0.55, 3.60); TT/CC (European subgroup): 0.81 (0.50, 1.33);
Neoadjuvant subgroup: 1.12 (0.49, 2.55) TT/CC (Palliative subgroup): 1.16 (0.65, 2.08);
TT/CC (Neoadjuvant subgroup): 0.81 (0.50, 1.33)
RR: response rate; OS: overall survival; OR: odds ratio; HR: hazard ratio; NR: not reporting; NSS: no statistical significance.
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platinum based chemotherapy
Response rate (RR) Seven studies (674patients) evalu-
ated the association between ERCC1 polymorphism and
RR [11,14,18,19,21,30,31]. All of the patients underwent
palliative chemotherapy. P value of heterogeneity test was
0.696 and a fixed-effect model was used. The pooled OR
for RR was 0.77 (95% CI: 0.54–1.11 Table 4), which sug-
gested that there was no significant association between
ERCC1 polymorphism and RR. Subgroup analysis was
performed according to ethnicity and evaluation criteria.
The pooled OR was 0.56 (95% CI: 0.32–0.97) for European
subgroup and 0.56 (95% CI: 0.32–1.00) for “Others” sub-
group, which suggested that RR was significantly higher in
C/C genotype compared with C/T or T/T genotypes.
However, the difference was not statistically significant in
Asian, RECIST or WHO subgroup (Table 4).
Six studies (794 patients) evaluated the association be-
tween GSTM1 polymorphism and RR [11,14,17,21,23,31].
P value of heterogeneity test was 0.734 and a fixed-effect
model was used. The pooled OR for RR was 1.16 (95% CI:
0.85–1.58; Table 5), which suggested that there was no sig-
nificant association between RR of patients with M- geno-
type and that of patients with the M+ genotype. Subgroup
analysis according to ethnicity, evaluation criteria andchemotherapy purpose also did not show significant asso-
ciation (Table 5).
Data of 8 studies (959 patients) could be used for
evaluating the association between GSTP1 polymorph-
ism and RR [11,14,17,21,23,24,30,31]. P value of hetero-
geneity test was less than 0.1 and a random-effect model
was used. The pooled OR for RR was 1.63 (95% CI:
0.98–2.70; Table 5), which suggested that patients with
G/G or A/G genotype had a higher RR compared with
A/A genotype, although the difference was not statisti-
cally significant. The result was not changed by using
the method of subgroup analysis according to ethnicity,
evaluation criteria and chemotherapy purpose (Table 5).
Data of 6 studies (794 patients) were available for
GSTT1 [11,14,17,21,23,31]. P value of heterogeneity test
was 0.664 and a fixed-effect model was used. Combined
analysis suggested that RR was higher in T+ genotype
compared with T- genotype (T-/T+: OR=0.67, 95% CI:
0.47–0.97; Table 5). When used the method of subgroup
analysis, the result was changed in Asian, RECIST and
neo-adjuvant subgroups, but not changed in European
or “Others” subgroups (Table 5).
Overall survival
Five studies (587 patients) evaluated the association be-
tween ERCC1 polymorphism and OS [18,20,22,26,30],
Table 4 The association between ERCC1 polymorphism and clinical outcomes
Study (reference) RR (n/N) OS (HR, 95% CI) Toxicity
Goekkurt 2006 [11] CC: 2/5; CT+TT: 11/44 NR NR
Ruzzo 2006 [14] CC: 21/38; CT+TT: 49/137 NR NR
Park 2011 [18] CC: 35/64; CT+TT: 23/44 TC/CC: 0.94 (0.556, 1.587); TT/CC: 1.918 (0.748, 4.919) NR
Han 2010 [19] CC: 12/23; CT+TT: 9/15 NR NR
Stocker 2009 [20] NR CT/CC: 0.72 (0.40, 1.31); TT/CC: 1.07 (0.59, 1.95) NR
Seo 2009 [21] CC: 11/42; CT+TT: 7/33 NR NSS
Liu 2011 [22] NR (CT+TT)/CC: 2.388 (1.448, 3.937) NR
Huang 2009 [26] NR (CT+TT)/CC: 1.072 (0.620, 1.855) NR
Keam 2008 [30] CC: 17/40; CT+TT: 15/33 (CT+TT)/CC: 1.251 (0.68, 2.302) NR
Goekkurt 2009 [31] CC: 9/21; CT+TT: 43/113 NR NSS
Combined analysis (OR/HR, 95CI %) OR: (CT+TT)/CC HR: (CT+TT)/CC ___
Total (Palliative chemotherapy): 0.77 (0.54, 1.11); Total: 1.5 (0.90, 2.49)
Palliative subgroup: 1.77 (0.94, 3.33);
RECIST subgroup: 0.89 (0.52, 1.53); Adjuvant subgroup: 1.07 (0.62, 1.85);
WHO subgroup: 1.13 (0.45, 2.85);
All studies reported the data were
Others subgroup: 0.56 (0.32, 1.00); Asian.
Asian subgroup: 0.98 (0.61, 1.59);
European subgroup: 0.56 (0.32, 0.97)
RR: response rate; OS: overall survival; OR: odds ratio; HR: hazard ratio; NR: not reporting; NSS: no statistical significance.
Wang et al. BMC Gastroenterology 2012, 12:137 Page 7 of 13
http://www.biomedcentral.com/1471-230X/12/137but the studies by Park et al. and Stocker et al. could not
be used for meta-analysis, which reported no significant
association was observed between ERCC1 polymorphism
and OS [18,20]. Therefore 3 Asian studies (301 patients)
were used for combined analysis [22,26,30]. P value of
heterogeneity test was less than 0.1 and a random-effect
model was used. Meta-analysis showed that patients
with C/C genotype had a longer OS compared with C/T
or T/T genotypes; however, the difference was not statis-
tically significant [(CT+TT)/CC: HR=1.50, 95% CI:
0.90–2.49; Table 4]. The results were not changed by
subgroup analysis considering chemotherapy purpose.
Sensitivity analysis identified that the study reported by
Liu et al. [22] was the main source of heterogeneity.
(Additional file 3: Figure S3)
Data of 3 studies (441 patients) could be used for
assessing the association between GSTM1 polymorph-
ism and OS [17,23,26]. P value of heterogeneity test was
0.59 and a fixed-effect model was used. Meta-analysis
showed a longer OS in M+ genotype compared with
M- genotype; however, the difference was not statistically
significant (M-/M+: HR=1.23, 95% CI: 0.98–1.55; Table 5).
The result was consistent by using the method of subgroup
analysis considering ethnicity and chemotherapy purpose
(Table 5). (Additional file 4: Figure S4)
Eight studies (959 patients) reported evaluated the as-
sociation between GSTP1 polymorphism and OS
[11,14,17,22-24,26,30]. Among them 4 studies (393patients) used dominant model (GG/AG vs AA)
[22,24,26,30], three (514 patients) used codominant
model (GG vs AA, AG vs AA) [14,17,23], and one (52
patients) used recessive model [11]. Therefore, we com-
bined the data of included studies which used dominant
and codominant model respectively. The results of
meta-analysis showed that G/G or G/A genotypes were
associated with a longer OS compared with A/A geno-
type (Table 5). (Additional file 5: Figure S5)
HR of 3 studies (473 patients) were available for
GSTT1 [17,23,31]. P value of heterogeneity test was less
than 0.1 and a random-effect model was used. Com-
bined analysis suggested that there was no significant as-
sociation between GSTT1 polymorphism and OS [T-/T+:
HR=1.14, 95% CI: 0.68–1.90; Table 5]. However, in Asian
subgroup we could see a longer OS without statistical sig-
nificance in T- genotype compared with T+ genotype
(Table 5). (Additional file 6: Figure S6)Toxicity
Data of 2 included studies (228 patients) were applicable
for analyzing the association between ERCC1-118 poly-
morphism and toxicity [21,31], and no significant associ-
ation was identified. Two studies (226 patients) evaluated
the association between GSTP1 polymorphism and tox-
icity [24,31], and they both found that patients with
GSTP1-105 A/A genotype were at significantly higher risk
Table 5 The association between GSTs polymorphisms and clinical outcomes
Study (reference) RR (n/N) OS (HR, 95%CI) Toxicity
Goekkurt 2006 [11] GSTM1: M-: 9/32; M+: 4/18 NR NR
GSTP1: AA: 7/30; GA+GG: 6/18 GG/(GA+AA): 0.65 (0.43, 1.00) NR
GSTT1: T-: 8/38; T+: 5/12 NR NR
Ruzzo 2006 [14] GSTM1: M-: 36/78; M+: 34/97 NR NR
GSTP1: AA: 20/87; GA+GG: 50/88 GG/AA: 0.58 (0.43, 0.80) NR
GSTT1: T-: 6/21; T+: 64/154 GA/AA: 0.54 (0.40, 0.74) NR
NR
Shim 2010 [17] GSTM1: M-: 48/124; M+: 29/76 M-/M+: 1.10 (0.80, 1.51) NR
GSTP1: AA: 46/133 AG/AA: 1.12 (0.79, 1.58) NR
GA+GG: 31/67 GG/AA: 0.76 (0.33, 1.77) NR
GSTT1: T-: 40/106; T+: 37/94 T-/T+: 0.77 (0.57, 1.06)
Seo 2009 [21] GSTM1: M-: 12/49; M+: 6/26 NR NR
GSTP1: AA: 10/47; GA+GG: 8/28 NR NR
GSTT1: T-: 8/39; T+: 10/36 NR NR
Liu 2011 [22] GSTP1: NR (GG+AG)/AA: 0.53 (0.36, 0.80) NR
Ott 2008 [23] GSTM1: M-: 15/52; M+: 13/60 M-/M+: 1.38 (0.92, 2.08) NR
GSTP1: AA: 12/55; GA+GG: 21/77 AG/AA: 0.80 (0.55, 1.15) NR
GSTT1: T-: 5/23; T+: 24/87 GG/AA: 0.95 (0.53, 1.71) NR
T-/T+: 1.09 (0.69, 1.72)
Li 2010 [24] GSTP1: AA: 17/44; GA+GG: 29/41 (GG+AG)/AA: 0.44 (0.25, 0.78) SS
Huang 2009 [26] GSTM1: NR M-/M+: 1.425 (0.822, 2.469) NR
GSTP1: NR (GG+AG)/AA: 0.471 (0.252, 0.878) NR
Keam 2008 [30] GSTP1: AA: 22/44; GA+GG: 10/29 (GG+AG)/AA: 0.621 (0.452, 1.606) NR
Goekkurt 2009 [31] GSTM1: M-: 26/72; M+: 26/62 NR NR
GSTP1: AA: 26/64; GA+GG: 26/69 NR SS
GSTT1: T-: 5/23; T+: 47/111 T-/T+: 1.94 (1.14, 3.32) NR
Combined analysis(OR/HR, 95CI%) GSTM1(OR), M-/M+ Total: 1.16 (0.85, 1.58) GSTM1(HR), M-/M+ Total: 1.23 (0.98, 1.55) ___
RECIST subgroup: 1.07 (0.66, 1.74) Asian subgroup: 1.17 (0.89, 1.55)
Others subgroup: 1.23 (0.82, 1.84) European subgroup: 1.38 (0.92, 2.07)
Asian subgroup: 1.04 (0.62, 1.74) Palliative subgroup: 1.10 (0.80, 1.51)
European subgroup: 1.24 (0.84, 1.82) Adjuvant subgroup: 1.42 (0.82, 1.47)
Palliative subgroup: 1.04 (0.73, 1.49) Neoadjuvant subgroup: 1.38 (0.92, 2.07)
Neoadjuvant subgroup: 1.59 (0.86, 2.92) GSTP1(HR), (GG+AG)/AA,
Total: 0.51 (0.39, 0.67)
GSTP1(OR), (GG+AG)/AA
Palliative subgroup: 0.52 (0.39, 0.70)
Adjuvant subgroup: 0.47 (0.25, 0.88)
Total: 1.63 (0.98, 2.70) All studies reported the data were Asian.
RECIST subgroup: 1.60 (0.98, 2.60) GSTP1(HR), GG/AA, Total: 0.66 (0.51, 0.85)
WHO subgroup: 0.53 (0.20, 1.38)
Others subgroup: 2.1 (0.93, 4.74) Asian subgroup: 0.76 (0.33, 1.76)
Asian subgroup: 1.51 (0.72, 3.16) European subgroup: 0.65 (0.49, 0.85)
European subgroup: 1.74 (0.77, 3.91) Palliative subgroup: 0.60 (0.45, 0.80)
Palliative subgroup: 1.67 (0.93, 2.99) Neoadjuvant subgroup: 0.95 (0.53, 1.71)
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Table 5 The association between GSTs polymorphisms and clinical outcomes (Continued)
Neoadjuvant subgroup: 1.34 (0.60, 3.03) GSTP1(HR), AG/AA, Total: 0.78 (0.51, 1.20)
GSTT1(OR), T-/T+ Total: 0.67 (0.47, 0.97) RECIST subgroup: 0.79 (0.49, 1.27) Asian
subgroup: 1.12 (0.79, 1.58)
Others subgroup: 0.53 (0.29, 0.97) European subgroup: 0.65 (0.44, 0.95)
Asian subgroup: 0.87 (0.52, 1.43) Palliative subgroup: 0.77 (0.38, 1.58)
European subgroup: 0.51 (0.29, 0.88) Neoadjuvant subgroup: 0.80 (0.55, 1.16)
Palliative subgroup: 0.67 (0.45, 0.99) GSTT1(HR), T-/T+ Total: 1.14 (0.68, 1.90)
Neoadjuvant subgroup: 0.73 (0.24, 2.18)
Asian subgroup: 0.77 (0.56, 1.05)
European subgroup: 1.43 (0.81, 2.51)
Palliative subgroup: 1.19 (0.48, 2.94)
Neoadjuvant subgroup: 1.09 (0.69, 1.72)
RR: response rate; OS: overall survival; OR: odds ratio; HR: hazard ratio; NR: not reporting; SS: statistical significance.
Wang et al. BMC Gastroenterology 2012, 12:137 Page 9 of 13
http://www.biomedcentral.com/1471-230X/12/137of experiencing hematological and neurological toxicity
compared with patients with A/G or G/G genotype.
Discussion
Recently, a growing body of evidence suggests interindi-
vidual variation in drug-metabolizing enzymes (such as
TS and MTHFR), nucleotide excision repair systems
(such as ERCC1), and GST families may affect antican-
cer drug efficacy for GC. However, the association
remains controversial and uncertain. Therefore, we con-
ducted this systematic review aiming to provide a com-
prehensive and up-to-date overview on the biomarkers
that can be served as predictive surrogates for clinical
outcomes in patients with GC. To our knowledge, this is
the first meta-analysis evaluating genetic polymorphisms
in predicting clinical outcomes of GC patients treated
with platinum/5-Fu-based chemotherapy. In this study,
we found TS and MTHFR polymorphisms were asso-
ciated with clinical outcomes of 5-Fu based chemother-
apy, and sequences for ERCC1 and GSTs had a
relationship with clinical outcomes of platinum based
chemotherapy.
The strengths of this systematic review were its well
defined search strategy and selection of study according
to the strict inclusion criteria. In addition, we performed
subgroup analysis in order to reduce heterogeneity
caused by ethnicity and evaluation criteria. These factors
increased the reliability of our review. However, our
study was not faultless. Firstly, potential selection bias
was introduced because of different inclusion criteria in
included studies. For example, Stocker et al. [20]
included locally advanced GC patients without distant
metastasis, but Shim et al. [17] included patients with
recurrent or metastatic GC. Secondly, chemotherapy
regimen was different among included studies, but this
factor was not taken into consideration when perform-
ing meta-analysis in lack of coherence of primary data.Finally, it was impossible for us to identify all relevant
literatures, even though we made great efforts. More-
over, publication bias might exist and we did not draw a
funnel plot because of uncomplete data in included
studies.
The fluoropyrimidine 5-Fu has been the standard
agent in GC chemotherapy, either as a single drug or in
combination with other agents. TS, the rate-limiting en-
zyme in de novo pyrimidine biosynthesis, is a target en-
zyme of 5-FU. Recent evidence indicates that elevated
TS in GC, in both mRNA and protein levels, are asso-
ciated with clinical resistance to 5-Fu and consequently
with poor outcome of the patients receiving 5-FU ther-
apy [29]. And high TS expression is now well known to
be associated with polymorphism of the 28-base pair
tandem repeat sequence (VNTR) in the TS promoter en-
hancer region (TSER) [35]. The presence of triple
repeats (3R/3R) has been shown to be associated with
higher TS expression [35], with resultant lower fluorour-
acil efficacy [36], while double repeat homozygous
(2R/2R) has provided better clinical outcomes after 5-Fu-
based chemotherapy [37]. In our studies, we found there
was no significant association between TS polymorphism
in VNTR and RR [(2R2R+2R3R)/3R3R: OR=0.92, 95% CI:
0.62–1.37]; and the result was not changed by using the
method of subgroup analysis according to ethnicity, evalu-
ation criteria or chemotherapy purpose. However, a sig-
nificantly longer OS was observed in 3R/3R genotype
compared with the 2R/2R or 2R/3R genotypes [(2R2R
+2R3R)/3R3R: HR=1.29, 95% CI: 1.02–1.64]. This result
was opposite to previous reports [37]. Recently, some
researchers found similar phenomena with ours, consider-
ing survival or response to 5-Fu treatment in patients with
3R/3R gene polymorphism better than [38], or equal to
that with the 2R/2R genotype [39]. This contrary phenom-
ena suggests that the whole transcriptional activity of TS
is not always dependent on the number of the tandem
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including polymorphism of 6-base pair (bp) insertion
(6+/6+ genotype) in the 3’ untranslated region and a G/C
polymorphism in the 3R VNTR allele can possibly explain
these inconclusive data [40]. Therefore, a single polymorph-
ism of TS is not sufficient to explain changes in the clinical
benefit of 5-Fu, and complex combinations of variants
should be considered.
MTHFR is another central enzyme for maintaining
DNA integrity and stability by regulating the folate pool.
Studies found that MTHFR C677T single-nucleotide
polymorphism (alanine to valine substitution at codon
222) was associated with reduced enzymatic activity
[41]. Theoretically, decreased MTHFR activity confers a
more effective TS inhibition and resultant increased
5-Fu efficacy. And this was confirmed by previous stud-
ies, which reported the highest clinical RR to 5-Fu in
subjects with TT mutant homozygous [42]. However,
our meta-analysis showed that there was no correlation
between MTHFR C677T single-nucleotide polymorph-
ism and clinical outcomes of 5-Fu-based chemotherapy,
whether RR [(CT+TT)/CC: OR=1.12, 95% CI: 0.49–2.55]
or OS (CT/CC: HR=1.10, 95% CI: 0.67–1.79; TT/CC:
HR=0.94, 95% CI: 0.65–1.37). Considering chemotherapy
purpose and the variation of allele frequency in different
ethnicity (TT is 1% or less among Blacks from Africa or
the United States, and 10% in Caucasians) [43], we con-
ducted subgroup-analysis but failed to reveal significant
association (Table 3). As was discussed for TS poly-
morphism, the discrepant results may be ascribed to
other gene polymorphism regulating MTHFR activity,
such as A1298C single-nucleotide polymorphism.
Platinum derivatives, mainly cisplatin but more re-
cently oxaliplatin, have been widely used for treating
GC. Resistance to platinum is attributable to enhanced
DNA repair. Genes of the NER pathway plays a key role
in recognition and repair of damaged DNA caused by
platinum compounds. Functional polymorphism of
ERCC1-C118T has been demonstrated to impact clinical
outcome of patients receiving platinum-based chemo-
therapy [44]. Some researchers found that patients with
the ERCC1 118 T/T genotype were more likely to re-
spond to oxaliplatin-based chemotherapy than carriers
of the other genotypes in colorectal and pancreatic can-
cer [45,46]. However, several studies indicated that no
significant association was found between ERCC1 codon
118 polymorphism and platinum sensitivity [14,47]. In
this study, we found no significant association between
ERCC1 codon 118 polymorphism and clinical outcomes
(Table 4). Nevertheless, a higher response rate was
found in patients with C allele in European subgroup
[(CT+TT)/CC: OR=0.56, 95% CI: 0.32–0.97]. This was
consistent with a recent study on advanced GC treated with
fluorouracil/cisplatin palliative chemotherapy [48]. Thepossible reasons for controversial results is that ERCC1
codon 118 polymorphism is in linkage disequilibrium
with other ERCC1 mutations or polymorphisms that dir-
ectly affect its expression can not be ruled out. Other
possible reasons may be variable doses and schedules of
platinum-based therapy, different kind of cancers and
variable tumor stages. Studies with large sample size
using the method of multi-variant analyses may help us
to give more persuasive data on the putative association
in future.
Through conjugation to glutathione, GST is a member
of isozymes’ family which plays an important role in the
detoxification of platinum-based chemotherapy. Some
isoenzymes (in particular GSTM1, P1 and T1) are
involved in this process. It has been reported that the
GSTP1-A105G polymorphism was associated with prog-
nosis of gastric and colorectal cancer patients receiving
platinum-based chemotherapy (the mutant 105 G/G
homozygous involving with survival benefits [11,49],
while wild type 105 A/A homozygous associated with
unfavorable clinical outcomes [14]). In this study, we
found that G/G or G/A genotypes were associated with
a longer OS compared with A/A genotype [(GG+AG)/
AA: HR=0.51, 95% CI: 0.39–0.67], which was concord-
ant with previous studies. With regard to polymorphism
in the GSTT1 and GSTM1, which lead to complete loss
of enzymatic activity, the results are divergent. Null gen-
otypes of GSTM1 and GSTT1 could provide significant
survival benefit in breast cancer [50], but other studies
in colorectal cancer reported inconsistent results [49,51].
We found that there was no significant association be-
tween GSTM1 polymorphism and clinical outcomes;
however, RR was higher in T+ genotype compared with
T- genotype [T-/T+: OR=0.67, 95% CI: 0.47–0.97;
Table 5]. These discrepant results may be ascribed to
differences in the distribution of the GST families and
differences in enzymatic activity for drug detoxification
in various tissues.
Multiple genes are involved in the mechanisms with
complex interplay. Despite still being in the investiga-
tional stage, efforts for predicting clinical outcomes
using expression profiles of multiple key genes have
been also intensively performed in various malignancies,
including GC [11,14,26,52]. This movement from single
gene polymorphism to a more comprehensive pathway
evaluation could undoubtedly offer a more tailored ap-
proach to chemotherapy by providing a more effective
biomarker through a better understanding of the genetic
and molecular basis underlying variable drug response
among patients, and ultimately improve treatment out-
comes. Meanwhile, we must notice that never single
agents are delivered. Poly-chemotherapy which com-
bines several drugs (mainly 5-Fu and platinum) is the
main chemotherapy regime currently. Whether the
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drug interactions is worthy of studying. In addition,
attentions should be paid for the association between
genetic polymorphisms and adverse events. In this meta-
analysis, very few included studies evaluated this associ-
ation, and the evaluation criteria were different. There-
fore, we just described the results of included studies
without combined analysis. More studies using uniform
evaluation standard are needed to assess the association
between genetic polymorphisms and chemotherapy tox-
icity in future.
Conclusion
In conclusion, polymorphisms of ERCC1, GSTs, TS and
MTHFR were closely associated with clinical outcomes
of GC patients treated with platinum/5-Fu-based
chemotherapy. Studies with large sample size using the
method of multi-variant analyses may help us to give
more persuasive data on the putative association in fu-
ture. Additionally, targeted agents may offer new tools
in GC treatment under the circumstance of inevitable
side effects of chemotherapy.
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